Plasma homocysteine concentrations have been associated with the risk of stroke, but its relevance to secondary vascular events and mortality after stroke remains unclear because of inconsistent results from clinical trials. The aim of the present study was to investigate whether plasma homocysteine levels and the MTHFR (methylenetetrahydrofolate reductase) variant C677T contributed to the risk of stroke recurrence and all-cause mortality in a large prospective cohort of stroke patients in a Chinese population. A total of 1823 stroke patients (age, 35-74 years) were recruited during 2000-2001 and prospectively followed-up for a median of 4.5 years. During the followup, 347 recurrent strokes and 323 deaths from all-causes were documented. After adjustment for age, gender and other cardiovascular risk factors, a high homocysteine concentration was associated with an increased risk of 1.74-fold for stroke recurrence {RR (relative risk), 1.74 [95 % CI (confidence interval), 1.3-2.3]; P < 0.0001} and 1.75-fold for all-cause mortality [RR, 1.75 (95 % CI, 1.3-2.4); P < 0.0001] when highest and lowest categories were compared. Spline regression analyses revealed a threshold level of homocysteine for stroke recurrence. By dichotomizing homocysteine concentrations, the RRs were 1.31 (95 % CI, 1.10-1.61; P = 0.016) for stroke recurrence and 1.47 (95 % CI, 1.15-1.88; P < 0.0001) for all-cause mortality in patients with homocysteine levels 16 μmol/l relative to those with levels <16 μmol/l. The association of elevated plasma homocysteine concentrations with all-cause mortality was mainly due to an increased risk of cardiovascular deaths. No significant association was found between MTHFR C677T and stroke recurrence or mortality. In conclusion, our findings suggest that elevated homocysteine concentrations can predict the risk of stroke recurrence and mortality in patients with stroke.
INTRODUCTION
Stroke is a leading cause of death and disability in China. Each year, 2.5 million people have a stroke, and more than 1 million die from stroke-related causes. Survivors often require long-term care and are at high risk of recurrence. Conventional vascular risk factors, including age, hypertension, dyslipidaemia, diabetes and smoking, have been associated with recurrent stroke, but these characteristics do not fully explain all of the events [1] . Identification of modifiable risk factors may lead to more effective primary and secondary prevention of stroke.
In experimental studies, homocysteine causes oxidative stress, endothelium dysfunction and atherothrombosis [2] . Case-control and prospective studies have shown that the plasma homocysteine concentration is a strong, graded and independent risk factor for coronary heart disease and stroke [3] [4] [5] . Although homocysteinelowering trials have failed to confirm a reduction in overall cardiovascular risk [6, 7] , this may benefit the subjects with specific cardiovascular disease end points, notably stroke [8] . In the VISP (Vitamin Intervention for Stroke Prevention) trial, Toole et al. [6] have also found that a 3 μmol/l lower total homocysteine level was associated with a 10 % lower risk of recurrent stroke. The HOPE (Heart Outcomes Prevention Evaluation) study reported that folic acid supplementation reduces the risk of stroke 24 % in subjects with high cardiovascular risk profiles [9] . A population-based survey has shown that stroke mortality decreased significantly during the period of 1998-2002 in the U.S.A. and Canada after the implementation of folic acid fortification of grain products [10] .
The relationship between homocysteine and secondary vascular events or death after stroke remains inconsistent due to short-term follow-up [6, 11] or small sample size [12, 13] . Therefore the aim of the present study was to investigate whether elevated plasma homocysteine levels contribute to the risk of stroke recurrence and all-cause mortality in a large prospective stroke population with a median 4.5-year follow-up. We also assessed the MTHFR (methylenetetrahydrofolate reductase) variant C677T (rs1801133) in relation to stroke recurrence and mortality.
MATERIALS AND METHODS

Study population
The Multicenter Chinese Stroke Study has been described previously [14, 15] . Briefly, 2000 consecutive stroke patients (age, 35-74 years) were recruited from November 2000 to November 2001 from seven clinical centres. Three subtypes of stroke were included: cerebral thrombosis (atherothrombosis), lacunar infarction (lacunar) and ICH (intracerebral haemorrhage). Confirmation of stroke was based on the results of strict neurological examination and CT (computer tomography) scans or MRI (magnetic resonance imaging) according to ICD-9 (9th revision of the International Classification of Diseases). Stroke was diagnosed as a sudden onset of non-convulsive and focal neurological deficit persisting for > 24 h. Atherothrombotic stroke was defined as an occlusion or > 50 % stenosis of a major brain artery or branch cortical artery on duplex sonography or angiography, and corresponding to the clinical features of cerebral cortical, brain stem or cerebellar dysfunction; no definite cardiac source of embolism; cortical, cerebellar, brain stem or subcortical infarct was 1.5 cm in diameter on CT or MRI [16] . Lacunar infarction was diagnosed if the patient had one of the characteristic clinical lacunar syndromes, and CT or MRI showed either normal or a deep focal infarction in the brainstem or subcortical region with a diameter of < 15 mm [16] . Other types of stroke (embolic stroke and subarachnoid haemorrhage) and severe systemic diseases (collagenosis, inflammation, liver, neoplastic or renal diseases) were exclusion criteria.
Subjects with indefinite diagnosis (n = 24), unavailable blood samples (n = 76) or insufficient DNA (n = 77) were excluded, and 1823 patients (age, 60.3 + − 9.4 years; 63.5 % male) remained eligible for the present study. Of these, a total of 1477 (81 %) stroke patients were enrolled because of an acute event within 3 days after stroke onset, and 346 (19 %) were included within 3-21 days after the onset. A complete medical history and the conventional vascular risk factors at baseline were recorded on hospital admission: smoking, alcohol intake, BMI (body mass index), SBP [systolic BP (blood pressure)], DBP (diastolic BP), family history of stroke, and history of hypertension and diabetes. This stroke population was followed up annually until 31 May 2006 by a standard questionnaire and telephone contact by physician investigators. Antihypertensive therapy during the follow-up was recorded.
The study was approved by the local ethics committees of the collaborating hospitals. All participants reported themselves as being of Han nationality and provided written informed consent.
Biochemical variables and plasma homocysteine assays
Fasting blood samples were collected at 6 weeks after stroke onset. Plasma was separated by centrifugation, and plasma and cell buffy coats were kept at −70
• C. Biochemical variables, including blood glucose, total cholesterol, triacylglycerols (triglycerides), and HDL (high-density lipoprotein)-cholesterol were assayed using an automatic analyser (Hitachi 7060). Plasma homocysteine was analysed by HPLC (HP1100; Hewlett Packard) coupled to a fluorescence detector using the method described by Durand et al [17] . All measurements were taken in a laboratory qualified by the CDC (Centers for Disease Control and Prevention) at FuWai hospital. 
Genotyping the MTHFR C677T variant
DNA was extracted from the buffy coat fraction of centrifuged blood using the QIAmp Blood Kit (Qiagen). The MTHFR variant C677T was detected by PCR-RFLP (restriction-fragment-length polymorphism). A 198-bp fragment was amplified with the primers 5 -TG-AAGGAGAAGGTGTCTGCGGGA-3 and 5 -AGG-ACGGTGCGGTGAGAGTG-3 . The C677T mutation creates a HinfI restriction site, so digestion of the PCR product of the mutant allele by this enzyme generates two fragments (175 and 23 bp) that were fractionated by electrophoresis on a 3 % (w/v) agarose gel. Reproducibility of the genotyping was confirmed by sequencing in 500 randomly selected samples, with 100 % agreement. 
Outcome assessment
The end points were recurrent strokes and deaths. Recurrent stroke was defined using the following criteria: there was clinical evidence of the sudden onset of a new focal neurological deficit with no apparent cause other than that of vascular origin occurring at any time after the index stroke; or there was clinical evidence of the sudden onset of an exacerbation of a previous focal neurological deficit with no apparent cause other than that of vascular origin occurring > 21 days after the index stroke [18] . All reports of stroke events were confirmed by a local neurologist, based on a direct review of patient's medical records and brain imaging. In those who had more than one recurrent stroke, only the first one was considered. Deaths were reported by family members, work associates and/or obtained from death certificates and medical records. They were coded according to ICD-9, and ICD-9 codes 390 to 459 were classified as cardiovascular deaths.
Statistical analysis
Participants were classified according to the quartiles of plasma homocysteine concentrations. For comparison of the clinical characteristics, ANOVA was used for continuous variables and the χ 2 test for categorical variables. Person-years of follow-up started from the date of diagnosis of the first index stroke, defined as the date of the confirmation of stroke based on the results of neurological examination and CT or MRI scan, until the date of a first recurrence of stroke, death or the end of the follow-up period (31 May 2006), whichever came first.
The Cox proportional hazards regression model was used to assess the association of plasma homocysteine or MTHFR C677T with the risk of stroke recurrence and all-cause mortality. Multivariate models were adjusted for age, gender and conventional vascular risk factors, including BMI, glucose, total cholesterol, HDLcholesterol, triacylglycerols, serum creatinine, hypertension, diabetes, family history of stroke, smoking status, alcohol intake, location of clinic centres, index stroke subtype and antihypertensive therapy. The Mantel extension test was used to test for linear trends [19] , and the median values of each category of plasma homocysteine were included in the model as a continuous variable. Next, non-parametric linearity analysis was performed to identity a threshold level of homocysteine in relation to stroke recurrence. Briefly, the continuous measurement of plasma homocysteine concentration was used to fit a restricted cubic spline model and to obtain a smooth representation of the RR (relative risk) as a function of homocysteine with adjustment for the effects of vascular risk factors mentioned above [20] .
The C statistic was used to evaluate the discriminatory ability of the model including homocysteine. In addition, ROC (receiver-operating-characteristic) curves were plotted for models with and without homocysteine. All reported P values are two-sided, and P < 0.05 is considered statistically significant. Analyses were performed with SPSS version 11.0.
RESULTS
The characteristics of the stroke patients divided by quartiles of plasma homocysteine concentrations are shown in Table 1 . Patients with a higher homocysteine level were more likely to have conventional vascular risk factors, including cigarette smoking, alcohol intake, family history of stroke and higher BP. During a median 4.5 (range, 0.1-6.0) years of follow-up for 1823 patients, 98 were lost due to emigration. No significant differences were found in baseline characteristics and MTHFR C677T frequencies between the follow-up and lost-to-follow-up subjects.
A total of 347 recurrent strokes and 323 deaths from all causes (183 from stroke or coronary heart disease and 140 from other causes) were documented. After adjustment for age, gender and conventional vascular risk factors, the plasma homocysteine concentration was associated with an increased risk of 1.74-fold for stroke recurrence {RR, 1.74 [95 % CI (confidence interval), 1.3-2.3]; P for trend < 0.0001} and 1.75-fold for all-cause mortality [RR, 1.75 (95 % CI, 1.3-2.4); P for trend < 0.0001] when the highest and lowest categories were compared (Table 2) . Further analyses showed that plasma homocysteine in the highest category was positively associated with cardiovascular death [RR, 1.88 (95 % CI, 1.2-2.7); P for trend = 0.006], but not with non-cardiovascular death [RR, 1.14 (95 % CI, 0.7-1.9); P for trend = 0.59]. We also examined the MTHFR variant C677T in relation to risk of stroke recurrence and mortality, but did not observe any significant associations (Table 2) .
Given the low proportion of stroke patients receiving antihypertensive treatment during follow-up, we did an additional analysis stratified by the presence or absence of antihypertensive therapy; however, the results were not significantly altered. Subgroup analyses showed that, in patients with the index atherothrombotic stroke or ICH, higher plasma homocysteine was associated with a risk of stroke recurrence as well as all-cause mortality (Table 3 ), but not in the subjects with lacunar stroke.
The linear trend test showed a positive association between plasma homocysteine levels and the risk of stroke recurrence, although the RR of stroke recurrence in the third quartile (14.7-19.7 μmol/l) of plasma homocysteine was slightly lower than that in the second quartile (11.5-14.6 μmol/l), which might be due to residual confounding from some unknown factor(s). By visual inspection, the restricted cubic spline curve confirmed the impression of a threshold of plasma homocysteine concentration in relation to the risk of stroke recurrence and all-cause or cardiovascular mortality (Figure 1 ), in concordance with the categorical analysis. Therefore we dichotomized the plasma homocysteine concentrations into two categories at the cut-off value of 16 μmol/l, which represents the top 75th percentile of the distribution of subjects. The RRs of elevated homocysteine level ( 16 μmol/l) were 1.31 (95 % CI, 1.10-1.61; P = 0.012) for stroke recurrence and 1.47 (95 % CI, 1.15-1.88; P = 0.001) for all-cause mortality. As the MTHFR variant C677T was correlated with homocysteine levels, we then carried out stratified analysis by C677T genotype. The positive association with stroke recurrence or mortality remained in each subgroup and was not substantially modified by the variant C677T (Table 4) . Tests for the interaction between plasma homocysteine and the variant C677T were not statistically significant. Elevated homocysteine levels ( 16 μmol) added predictive power to stroke recurrence or mortality in addition to conventional vascular risk factors (Figure 2) . 
DISCUSSION
In this large prospective cohort of stroke patients in a Chinese population, a higher homocysteine concentration was associated with an increased risk of stroke recurrence and all-cause mortality. The same association was not found for the MTHFR variant C677T. Moreover, elevated homocysteine levels ( 16 μmol/l) added predictive power to stroke recurrence and all-cause mortality in addition to conventional vascular risk factors. The association of homocysteine with all-cause mortality was mainly due to an increased risk of cardiovascular deaths.
The strengths of the present study included its prospective design, the high follow-up rates (94.6 %) and the long-term follow-up period. The large number of stroke patients in this cohort allowed us to examine the role of plasma homocysteine in different subtypes. To our knowledge, the present study provides evidence for the first time that elevated homocysteine concentrations play an important role in the long-term risk of stroke recurrence and mortality not only in patients with atherothrombotic stroke, but also in those with ICH.
It is generally accepted that plasma homocysteine has pro-coagulative effects and induces endothelial damage, which may lead to thrombotic vascular disease [2] . The mechanism underlying the effects of high homocysteine on haemorrhagic stroke has not yet been fully elucidated. Hofmann et al. [21] have shown that the induction of high homocysteine levels in Apoe (apolipoprotein E)-null mice enhances the expression and activity of key participants in vascular inflammation, atherogenesis, hypercoagulation status and vulnerability of the established atherosclerotic plaque. The level and activity of tissue-destructive enzymes, such as MMP-9 (matrix metalloproteinase-9), have been shown to be increased in mice with hyperhomocysteinaemia. These enzymes, present in the atherosclerotic plaque, may promote lesion instability and rupture. Thus higher homocysteine levels could cause either ischaemic stroke through its hypercoagulative effect or haemorrhagic stroke by promoting plaque rupture, which is consistently supported by the association between elevated homocysteine levels ( 16 μmol/l) and and increased risk of stroke in our previous study [14] .
In the present study, the MTHFR variant C677T was not associated with stroke recurrence or mortality. As shown by the upper limits of 95 % CIs of our RR estimates, we cannot exclude the possibility that we missed an association between C677T and a modestly higher risk of stroke recurrence due to chance; however, results from a previous study support that elevated plasma homocysteine increases the risk of recurrent coronary events in young patients irrespective of MTHFR C677T [22] . In addition, a common variant in the MTHFR gene, A1298C, has also been shown to be associated with elevated plasma homocysteine levels [23] . Therefore further investigations of other potential variants might be useful in identifying genetic modifiers for the first and recurrent episodes of stroke.
Our present study had some potential limitations. The homocysteine concentration depends partly on folate, vitamin B 12 and vitamin B 6 status [24] , which were not determined in the present study. It is possible that homocysteine is not the causal factor in the risk of stroke recurrence and mortality, but a marker of altered vitamin B or folate status. However, studies on the relationship between vitamin B or folate status and the risk of stroke remain inconsistent [25, 26] , suggesting that further investigations are needed to address this question. Another limitation was the lack of information on statin usage. Recently, there is increasing evidence that statins reduce stroke recurrence and may improve prognosis post-stroke [27] . Finally, the initial severity of stroke at the acute phase was not measured using the NIHSS (National Institutes of Health Stroke Scale), which has been recognized to be one of the potential predictors of prognosis after stroke.
In conclusion, the present prospective study of stroke patients in a Chinese population has suggested that higher plasma homocysteine concentrations predicted the risk of stroke recurrence and all-cause mortality in stroke patients in addition to conventional vascular risk factors. Our findings might serve as an additional incentive for the initiation of an intervention trial with homocysteine-lowering therapy for secondary prevention of vascular diseases including stroke.
